Hybrid stent and method of making

Patent metadata

Field	Value
Publication number	US-2016346102-A1
Application number	US-201615233585-A
Country	US
Kind code	A1
Filing date	Aug 10, 2016
Priority date	Apr 1, 2002
Publication date	Dec 1, 2016
Grant date	—

Abstract

A stent is formed by encasing or encapsulating metallic rings in an inner polymeric layer and an outer polymeric layer. At least one polymer link connects adjacent metallic rings. The stent is drug loaded with one or more therapeutic agent or drug, for example, to reduce the likelihood of the development of restenosis in the coronary arteries. The inner and outer polymeric materials can be of the same polymer or different polymer to achieve different results, such as enhancing flexibility and providing a stent that is visible under MRI, computer tomography and x-ray fluoroscopy.

First claim

1 - 41 . (canceled)

42 . A stent, comprising:
a metallic body having an undulating pattern including a plurality of longitudinally spaced-apart peaks and a plurality of longitudinally spaced-apart valleys; a polymeric material encasing the metallic body; and a plurality of links made from the polymeric material which extend between the longitudinally spaced-apart peaks and the longitudinally spaced-apart valleys, wherein each link has a first end and a second end, the first end of each link being attached to a peak or valley of the metallic body and the second end being attached to an adjacent peak or valley of the metallic body.

43 . The stent of claim 42 , wherein the polymeric material is radiopaque.

44 . The stent of claim 42 , wherein the polymeric material is taken from the group of polymers consisting of polyetheretherketone (PEEK), ethyl vinyl alcohol (EVOH), polyetherketone, polymethylmethacrylate, polycarbonate, polyphenylenesulfide, polyphenylene, polyvinylfluoride, polyvinylidene fluoride, polypropylene, polyethylene, poly(vinylidene fluoride-co-hexafluoropropylene), poly(ethylene-co-hexafluoropropylene), poly(tetrafluoroethyelene-co-hexafluoropropylene), poly(tetrafluoroethyelene-co-ethylene), polyethyleneterephthalate, polyimides, polyetherimide, ePTFE, polyurethanes, polyetherurethanes, polyesterurethanes, silicone, thermoplastic elastomer, polyether-amide thermoplastic elastomer, fluoroelastomers, fluorosilicone elastomer, styrene-butadiene-styrene rubber, styrene-isoprene-styrene rubber, polybutadiene, polyisoprene, neoprene, ethylene-propylene elastomer, chlorosulfonated polyethylene elastomer, butyl rubber, polysulfide elastomer, polyacrylate elastomer, nitrile rubber, a family of elastomers composed of styrene, ethylene, propylene, aliphatic polycarbonate polyurethane, polymers augmented with antioxidants, polymers augmented with image enhancing materials, polymers having a proton (H+) core, butadiene and isoprene and polyester thermoplastic elastomer and a di-block co-polymer of PET and caprolactone.

45 . The stent of claim 42 , wherein the metallic body is formed from a metal taken from the group of metals consisting of stainless steel, titanium, tantalum, nickel-titanium, cobalt-chromium, and tungsten.

46 . The stent of claim 42 , wherein the polymeric material is loaded with a therapeutic drug.

47 . The stent of claim 46 , wherein the therapeutic drug is taken from the group of drugs including one or more of everolimus, rapamycin, actinomycin D (ActD), or derivatives and analogs thereof; synonyms of actinopmycin D including dactinomycin, actinomycin IV, actinomycin 11, actinomycin X1, and actinomycin C1; antiproliferative substances including antineoplastic, antinflammatory, antiplatelet, anticoagulant, antifibrin, antithomobin, antimitotic, antibiotic, antioxidant substances, taxol (paclitaxel and docetaxel), anticoagulants, antifibrins, sodium heparin, low molecular weight heparin, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogs, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein, llb/llla platelet membrane receptor antagonist, recombinant hirudin, thrombin inhibitor methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, adriamycin, mutamycin; angiopeptin, angiotensin converting enzyme inhibitors; calcium channel blockers; colchicine fibroblast growth factor (FGF) antagonists; fish oil (omega 3-fatty acid); histamine antagonist; monoclonal antibodies (such as PDGF receptors); nitroprusside; phosphodiesterase inhibitors; prostaglandin inhibitor (a PDGF antagonist); serotonin blockers; steroids; thioprotease inhibitors; triazolopyrimidine (a PDGF antagonist); and nitric oxide.

48 . The stent of claim 42 , wherein the stent is configured so that it is visible under any of x-ray fluoroscopy, computer tomography, or MRI.

49 . A stent, comprising:
a stent body made from a metallic material, the stent body having crowns extending circumferentially to create open spaces on the stent body; and a polymeric material encasing the stent body and forming polymeric links which extend within the open spaces formed on the metallic body, wherein each link has a first end and a second end, the first end being attached to a crown and the second end being attached to an adjacent crown.

50 . The stent of claim 49 , wherein the polymeric links are formed from the polymeric material encasing the stent body.

51 . The stent of claim 49 , wherein the metallic body is formed from a metal taken from the group of metals consisting of stainless steel, titanium, tantalum, nickel-titanium, cobalt-chromium, and tungsten.

52 . The stent of claim 49 , wherein the polymeric material is loaded with a therapeutic drug.

53 . The stent of claim 52 , wherein the therapeutic drug is taken from the group of drugs including one or more of everolimus, rapamycin, actinomycin D (ActD), or derivatives and analogs thereof; synonyms of actinopmycin D including dactinomycin, actinomycin IV, actinomycin 11, actinomycin X1, and actinomycin C1; antiproliferative substances including antineoplastic, antinflammatory, antiplatelet, anticoagulant, antifibrin, antithomobin, antimitotic, antibiotic, antioxidant substances, taxol (paclitaxel and docetaxel), anticoagulants, antifibrins, sodium heparin, low molecular weight heparin, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogs, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein, llb/llla platelet membrane receptor antagonist, recombinant hirudin, thrombin inhibitor methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, adriamycin, mutamycin; angiopeptin, angiotensin converting enzyme inhibitors; calcium channel blockers; colchicine fibroblast growth factor (FGF) antagonists; fish oil (omega 3-fatty acid); histamine antagonist; monoclonal antibodies (such as PDGF receptors); nitroprusside; phosphodiesterase inhibitors; prostaglandin inhibitor (a PDGF antagonist); serotonin blockers; steroids; thioprotease inhibitors; triazolopyrimidine (a PDGF antagonist); and nitric oxide.

54 . The stent of claim 49 , wherein the stent is configured so that it is visible under any of x-ray fluoroscopy, computer tomography, or MRI.

55 . A stent, comprising:
a stent body made from a metallic material and having a longitudinal stent axis, the stent body including an undulating structural support extending circumferentially along the longitudinal stent axis to create discrete open spaces longitudinally along the longitudinal stent axis; a polymeric material encasing the stent body; and polymeric links connecting adjacent portions of the structural support together, each polymeric link being located adjacent to an open space.

56 . The stent of claim 55 , wherein the polymeric links are formed from the polymeric material encasing the stent body.

57 . The stent of claim 55 , wherein the metallic body is formed from a metal taken from the group of metals consisting of stainless steel, titanium, tantalum, nickel-titanium, cobalt-chromium, and tungsten.

58 . The stent of claim 55 , wherein the polymeric material is loaded with a therapeutic drug.

59 . The stent of claim 58 , wherein the therapeutic drug is taken from the group of drugs including one or more of everolimus, rapamycin, actinomycin D (ActD), or derivatives and analogs thereof; synonyms of actinopmycin D including dactinomycin, actinomycin IV, actinomycin 11, actinomycin X1, and actinomycin C1; anti

Assignees

• Abbott Cardiovascular Systems Inc

Inventors

• Prabhu Santosh

Classifications

• A61F2210/0076

  multilayered, e.g. laminated structures · CPC title

• A61L31/18

  Materials at least partially X-ray or laser opaque · CPC title

• A61F2250/0067

  Means for introducing or releasing pharmaceutical products into the body · CPC title

• A61F2230/0069

  cylindrical · CPC title

• A61L31/022

  Metals or alloys · CPC title